DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» ChAdOx1
ChAdOx1
Assessment Report COVID-19 Vaccine Astrazeneca EMA/94907/2021
Chadox1 Ncov-19 Vaccine Prevents SARS-Cov-2 Pneumonia in Rhesus Macaques
Transcriptomic Profiling of Dromedary Camels Immunised with a MERS
Clinical Advances in Viral-Vectored Influenza Vaccines
Jenner Institute Complementary Vaccines Platform Technologies
Viral Vectors for COVID-19 Vaccine Development
'Astrazeneca' Covid-19 Vaccine
Safety and Immunogenicity of Chadox1 Ncov-19 Vaccine Administered in a Prime-Boost Regimen in Young and Old Adults (COV002)
Novel Bivalent Viral-Vectored Vaccines Induce Potent Humoral
Slides for Yuri
COVID-19 Vaccine (Chadox1-S [Recombinant]) Astrazeneca COVID-19 Vaccine Supplier: Astrazeneca COVISHIELD Supplier: Verity Pharmaceuticals
COVID-19 Vaccine Astrazeneca, Solution for Injection COVID-19 Vaccine (Chadox1-S [Recombinant])
Novel Bivalent Viral-Vectored Vaccines Induce Potent Humoral
COVID-19 Vaccine Astrazeneca
Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus Chadox2 As a Vectored Vaccine
Chikungunya: an Emerging Rheumatological Pandemic?
B/Be/20/Bvw2
Chadox1 Ncov-19 Vaccination Prevents SARS-Cov-2 Pneumonia in Rhesus Macaques 2
Top View
Vaccitech Oncology Limited's Chadox1/MVA Prime-Boost
A Single Dose of Chadox1 Chik Vaccine Induces Neutralizing Antibodies Against Four Chikungunya Virus Lineages in a Phase 1 Clinical Trial
Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus a in Healthy Adults
Chadox1-S [Recombinant])
Safety and Immunogenicity of the Chadox1 Ncov-19 Vaccine Against SARS-Cov-2: a Preliminary Report of a Phase 1/2, Single-Blind, Randomised Controlled Trial
Efficacy of Chadox1 Ncov-19 (AZD1222) Vaccine Against SARS-Cov-2 Variant of Concern 202012/01 (B.1.1.7) : an Exploratory Analysis of a Randomised Controlled Trial
COVID-19 Vaccines: Viral Vector-Based
Phase 1/2 Trial of SARS-Cov-2 Vaccine Chadox1 Ncov-19 with a Booster Dose Induces Multifunctional Antibody Responses
Author Correction: Phase 1/2 Trial of SARS-Cov-2 Vaccine Chadox1 Ncov-19 with a Booster Dose Induces Multifunctional Antibody Responses Jordan R
Common Application Form for Viral Vectors Contained in Investigational Medicinal Products for Human Use1
Immunologic Dose-Response to Adenovirus-Vectored Vaccines In
L0015 a Phase I Study to Determine the Safety and Immunogenicity of A
Intracerebral Hemorrhage Associated with Vaccine-Induced Thrombotic Thrombocytopenia Following Chadox1 Ncovid-19 Vaccine in a Pregnant Woman by Daniela P
Interactions of Adenoviruses with Platelets and Coagulation and The
Prot SAP 000.Pdf
Chadox1 Ncov-19 Protection Against SARS-Cov-2 in Rhesus Macaque and Ferret Challenge Models
COVID-19 VACCINE ASTRAZENECA – Chadox1-S - Astrazeneca Pty Ltd – PM-2020-06115-1- 2 FINAL 15 February 2021
Interim Recommendations for Use of the Chadox1-S [Recombinant] Vaccine Against COVID-19 (Astrazeneca COVID-19 Vaccine AZD1222 Vaxzevria™, SII COVISHIELD™)
Safety of Chadox1 Ncov-19 Vaccine: Independent Evidence from Two EU States
Non-Human Primate-Derived Adenoviruses for Future Use As Oncolytic Agents?
OXFORD 2020: Meeting the Pandemic Challenge CONTENTS
Heterologous Combination of Chadox1 and MVA Vectors
Assessment of Immunogenicity and Neutralisation Efficacy of Viral
Vaxzevria, COVID-19 Vaccine (Chadox1-S [Recombinant])
Auspar: Chadox1-S
Thrombotic Thrombocytopenia After COVID-19 Vaccination: in Search of the Underlying Mechanism
The Relative Magnitude of Transgene-Specific Adaptive
A Systematic Review of Universal Influenza Vaccines in Clinical Trials
Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19
Vaxzevria (Previously COVID-19 Vaccine Astrazeneca)
Development and Evaluation of Influenza Vaccines Based on Adenovirus and MVA As Vectors Sarah C Gilbert T Cells Protect Against Influenza
COVID-19 Vaccine Janssen, INN-Ad26.COV2-S, Recombinant
Chadox1 Ncov-19 (AZD1222) Vaccine Candidate Significantly Reduces SARS-Cov-2 Shedding in Ferrets
Effectiveness of the Chadox1 Vaccine in the Elderly During SARS-Cov-2 Gamma Variant Transmission in Brazil